{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:42:29Z","timestamp":1780098149136,"version":"3.54.0"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2013,3,14]],"date-time":"2013-03-14T00:00:00Z","timestamp":1363219200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1002959","type":"journal-article","created":{"date-parts":[[2013,3,14]],"date-time":"2013-03-14T23:39:06Z","timestamp":1363304346000},"page":"e1002959","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":86,"title":["Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model"],"prefix":"10.1371","volume":"9","author":[{"given":"Libin","family":"Rong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Guedj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harel","family":"Dahari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Coffield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Perelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,3,14]]},"reference":[{"key":"ref1","unstructured":"World Health Organization. Hepatitis C. Fact sheet No. 164. Revised June 2011. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/index.html\" xlink:type=\"simple\">http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/index.html<\/ext-link>."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","article-title":"Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis","volume":"52","author":"AC Cardoso","year":"2010","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/hep.23504","article-title":"Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials","volume":"51","author":"T Awad","year":"2010","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"F Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"C Hezode","year":"2009","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"JG McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Responseguided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"KE Sherman","year":"2011","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"BR Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"AU Neumann","year":"1998","journal-title":"Science"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nature03153","article-title":"Modelling how ribavirin improves interferon response rates in hepatitis C virus infection","volume":"432","author":"NM Dixit","year":"2004","journal-title":"Nature"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1365-2893.2010.01348.x","article-title":"A perspective on modelling hepatitis C virus infection","volume":"17","author":"J Guedj","year":"2010","journal-title":"J Viral Hepat"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1615\/CritRevImmunol.v30.i2.30","article-title":"Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling","volume":"30","author":"L Rong","year":"2010","journal-title":"Crit Rev Immunol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jtbi.2010.08.036","article-title":"Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics","volume":"267","author":"J Guedj","year":"2010","journal-title":"J Theor Biol"},{"key":"ref14","article-title":"Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life","author":"J Guedj","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jhep.2010.11.001","article-title":"Treatment of chronic hepatitis C patients with the NS3\/4A protease inhibitor danoprevir (ITMN-191\/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study","volume":"54","author":"N Forestier","year":"2011","journal-title":"J Hepatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1086\/315661","article-title":"Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus","volume":"182","author":"AU Neumann","year":"2000","journal-title":"J Infect Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.gastro.2004.11.059","article-title":"Viral kinetics in hepatitis C or hepatitis C\/human immunodeficiency virus-infected patients","volume":"128","author":"KE Sherman","year":"2005","journal-title":"Gastroenterology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1177\/135965350901400402","article-title":"Rapid decrease of wild-type hepatitis C virus on telaprevir treatment","volume":"14","author":"BS Adiwijaya","year":"2009","journal-title":"Antivir Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1128\/JVI.02612-08","article-title":"Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon","volume":"83","author":"H Dahari","year":"2009","journal-title":"J Virol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1128\/JVI.01304-06","article-title":"Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells","volume":"81","author":"H Dahari","year":"2007","journal-title":"J Virol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1137\/0111030","article-title":"An algorithm for least-squares estimation of nonlinear parameters","volume":"11","author":"DW Marquardt","year":"1963","journal-title":"J Soc Indust Appl Math"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1128\/AAC.48.12.4784-4792.2004","article-title":"Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells","volume":"48","author":"K Lin","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"13001","DOI":"10.1128\/JVI.76.24.13001-13014.2002","article-title":"Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication","volume":"76","author":"KJ Blight","year":"2002","journal-title":"J Virol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3934\/mbe.2004.1.267","article-title":"An age-structured model of hiv infection that allows for variations in the production rate of viral particles and the death rate of productively infected cells","volume":"1","author":"PW Nelson","year":"2004","journal-title":"Math Biosci Eng"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1137\/060663945","article-title":"Mathematical analysis of age-structured HIV-1 dynamics with combination antiretroviral therapy","volume":"67","author":"L Rong","year":"2007","journal-title":"SIAM J Appl Math"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"S312","DOI":"10.1016\/S0168-8278(11)60778-2","article-title":"Modeling interferonalpha mediated inhibition kinetics of intracellular and extracellular HCV RNA during HCV infection in vitro","volume":"54","author":"H Dahari","year":"2011","journal-title":"J Hepatol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.gastro.2010.10.056","article-title":"Protease inhibitorresistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus","volume":"140","author":"T Shimakami","year":"2011","journal-title":"Gastroenterology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1146\/annurev-med-042010-085715","article-title":"Novel therapies for hepatitis C: insights from the structure of the virus","volume":"63","author":"DN Fusco","year":"2012","journal-title":"Annu Rev Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMe0901869","article-title":"A step forward in therapy for hepatitis C","volume":"360","author":"JH Hoofnagle","year":"2009","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"30ra32","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus","volume":"2","author":"L Rong","year":"2010","journal-title":"Sci Transl Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cld.2011.05.014","article-title":"Second-wave protease inhibitors: choosing an heir","volume":"15","author":"S Ciesek","year":"2011","journal-title":"Clin Liver Dis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2012.02.015","article-title":"Anti-hepatitis C virus drugs in development","volume":"142","author":"EA Schaefer","year":"2012","journal-title":"Gastroenterology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jhep.2011.01.046","article-title":"Antiviral activity, safety, and pharmacokinetics of danoprevir\/ritonavir plus PEG-IFN alpha-2a\/RBV in hepatitis C patients","volume":"55","author":"EJ Gane","year":"2011","journal-title":"J Hepatol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/infdis\/jir315","article-title":"Antiviral activity of danoprevir (ITMN-191\/RG7227) in combination with pegylated interferon alpha-2a and ribavirin in patients with hepatitis C","volume":"204","author":"N Forestier","year":"2011","journal-title":"J Infect Dis"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(10)61384-0","article-title":"Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, doseescalation trial","volume":"376","author":"EJ Gane","year":"2010","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/clpt.2010.35","article-title":"A comprehensive hepatitis C viral kinetic model explaining cure","volume":"87","author":"E Snoeck","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/lt.20572","article-title":"Kinetics of hepatitis C virus reinfection after liver transplantation","volume":"12","author":"KA Powers","year":"2006","journal-title":"Liver Transpl"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jhep.2004.12.017","article-title":"Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation","volume":"42","author":"H Dahari","year":"2005","journal-title":"J Hepatol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"M Gao","year":"2010","journal-title":"Nature"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev.immunol.25.022106.141602","article-title":"Flying under the radar: the immunobiology of hepatitis C","volume":"25","author":"LB Dustin","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"S Akira","year":"2006","journal-title":"Cell"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1073\/pnas.0408824102","article-title":"Immune evasion by hepatitis C virus NS3\/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF","volume":"102","author":"K Li","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1126\/science.1082604","article-title":"Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease","volume":"300","author":"E Foy","year":"2003","journal-title":"Science"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1128\/JVI.79.10.6291-6298.2005","article-title":"New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1","volume":"79","author":"DR Taylor","year":"2005","journal-title":"J Virol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1128\/AAC.05636-11","article-title":"Virologic escape during danoprevir (ITMN-191\/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution","volume":"56","author":"SR Lim","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"e1000745","DOI":"10.1371\/journal.pcbi.1000745","article-title":"A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants","volume":"6","author":"BS Adiwijaya","year":"2010","journal-title":"PLoS Comput Biol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"e1002339","DOI":"10.1371\/journal.pcbi.1002339","article-title":"A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection","volume":"8","author":"BS Adiwijaya","year":"2012","journal-title":"PLoS Comput Biol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s11538-012-9736-y","article-title":"Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor","volume":"74","author":"L Rong","year":"2012","journal-title":"Bull Math Biol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1055\/s-2003-41630","article-title":"Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b","volume":"23","author":"KA Powers","year":"2003","journal-title":"Semin Liver Dis"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/hep.21136","article-title":"Pharmacodynamics of PEG-IFN alpha differentiate HIV\/HCV coinfected sustained virological responders from nonresponders","volume":"43","author":"AH Talal","year":"2006","journal-title":"Hepatology"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jhep.2010.03.019","article-title":"Pharmacodynamics of PEG-IFN-alpha-2a in HIV\/HCV co-infected patients: Implications for treatment outcomes","volume":"53","author":"H Dahari","year":"2010","journal-title":"J Hepatol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jhep.2011.12.012","article-title":"Understanding silibinin&apos;s modes of action against HCV using viral kinetic modeling","volume":"56","author":"J Guedj","year":"2012","journal-title":"J Hepatol"}],"container-title":["PLoS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1002959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T09:03:15Z","timestamp":1688115795000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1002959"}},"subtitle":[],"editor":[{"given":"Becca","family":"Asquith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,3,14]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,3,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1002959","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,14]]}}}